Allakos (FRA:37Z) Construction In Progress : €0.07 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Allakos Construction In Progress?

Allakos's quarterly construction in progress increased from Sep. 2023 (€0.04 Mil) to Dec. 2023 (€0.06 Mil) and increased from Dec. 2023 (€0.06 Mil) to Mar. 2024 (€0.07 Mil).

Allakos's annual construction in progress declined from Dec. 2021 (€33.37 Mil) to Dec. 2022 (€0.40 Mil) and declined from Dec. 2022 (€0.40 Mil) to Dec. 2023 (€0.06 Mil).

Allakos Construction In Progress Historical Data

The historical data trend for Allakos's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allakos Construction In Progress Chart

Allakos Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

1.09

33.37

0.40

0.06

Allakos Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Construction In Progress	Get a 7-Day Free Trial															0.29	0.17	0.04	0.06	0.07

Allakos Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Allakos (FRA:37Z) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (FRA:37Z) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

ALLK:USA 37Z:Germany

Address

825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070

Website

https://www.allakos.com

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

Allakos (FRA:37Z) Headlines

No Headlines